Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial
Source : https://pubmed.ncbi.nlm.nih.gov/38749381/
A majority of patients with RET-driven cancers improved or remained stable on most QLQ-C30 domains, demonstrating favorable health-related quality of life as measured by the QLQ-C30 during long-term treatment with...
A majority of patients with RET-driven cancers improved or remained stable on most QLQ-C30 domains, demonstrating favorable health-related quality of life as measured by the QLQ-C30 during long-term treatment with selpercatinib.
Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)
Source : https://pubmed.ncbi.nlm.nih.gov/38122852/
The European Society for Radiotherapy and Oncology (ESTRO) has advocated the establishment of guidelines to optimise precision radiotherapy (RT) in conjunction with contemporary therapeutics for cancer care. Quality assurance in...
ESTRO's consensus recommendations for precision radiotherapy in breast cancer emphasize standardized protocols and quality assurance to optimize treatment outcomes and minimize variability in clinical practice and trials.
Selective RET Inhibitors (SRIs) in Cancer: A Journey from Multi-Kinase Inhibitors to the Next Generation of SRIs
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10778005/
Since the discovery of the RET gene in the early 1980s, multiple treatments have been developed that can inhibit abnormal RET signaling. The first treatments were repurposed multikinase inhibitors, however,...
Activating RET mutations and rearrangements have been identified as actionable drivers of oncogenesis in numerous cancer types, including NSCLC and thyroid cancers. Current clinical data demonstrate that patients can achieve long, deep, and meaningful responses with first-generation SRIs. Their use in clinical practice is likely to evolve...
Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11108846/
This post-hoc retrospective study describes long-term patient-reported outcomes (PROs) for REarranged during Transfection (RET)-altered non-small-cell lung cancer (NSCLC), medullary thyroid cancer (MTC), non-MTC thyroid cancer (TC), and tumor agnostic ...
PRO measures in LIBRETTO-001 were successfully incorporated with a high compliance rate across all visits for the QLQ-C30 (≥70%). In this analysis of PRO data, the majority of patients with RET-driven cancers remained stable or improved on most QLQ-C30 subscales at each study visit at 3 years for NSCLC and MTC and 2 years for TC and TA,...
Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11178778/
Tyrosine kinase (TK) fusions are frequently found in cancers, either as initiating events or as a mechanism of resistance to targeted therapy. Partner genes and exons in most TK fusions...
Tyrosine kinases are promising therapeutic targets in multiple cancer types; however, the formation and selection of tyrosine kinase fusions are not fully understood. Here, the authors develop a genome-wide fusion sequencing platform and identify mechanisms and patterns of fusion formation that have implication for targeted therapy.